TIDMAVCT

RNS Number : 2470E

Avacta Group PLC

28 June 2023

28 June 2023

Avacta Group plc

("Avacta" or the "Company" and, together with its subsidiary undertakings, the "Group")

Result of Annual General Meeting

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to announce that all resolutions have been duly passed by shareholders at the Annual General Meeting held today.

The full text of each resolution is set out in the Notice of Annual General Meeting, included in the 2022 Annual Report, which is available under the Investor Resources section of the Company's website https://avacta.com/investors/investor-resources/ .

All presentation materials provided to shareholders, including slide decks and posters, can also be found here.

- Ends-

For further information from Avacta Group plc, please contact:

 
 Avacta Group plc                                     Tel: +44 (0) 1904 21 7070 
  Alastair Smith, Chief Executive                                www.avacta.com 
  Officer 
  Tony Gardiner, Chief Financial Officer 
  Michael Vinegrad, Group Communications 
  Director 
 Stifel Nicolaus Europe Limited                       Tel: +44 (0) 207 710 7600 
  (Nomad and Broker)                                             www.stifel.com 
  Nicholas Moore / Nick Adams / Samira 
  Essebiyea / Nick Harland / Dhiren 
  Suares / William Palmer-Brown 
 FTI Consulting (Financial Media                       Tel: +44(0) 203 727 1000 
  and IR)                                           Avacta.LS@fticonsulting.com 
  Simon Conway / Alex Shaw 
 Zyme Communications (Trade and                        Tel: +44 (0)7891 477 378 
  Regional Media)                           lily.jeffery@zymecommunications.com 
  Lily Jeffery

About Avacta Group plc - www.avacta.com

Avacta Group plc is a life sciences company working to improve people's health and well-being through innovative oncology drugs and powerful diagnostics. Operating through two divisions, Diagnostics and Therapeutics, the Group's mission is to provide professionals and consumers with solutions that improve healthcare, fitness and well-being.

Avacta's Therapeutics Division, a clinical stage oncology drug innovator, is building a wholly owned pipeline of novel Affimer(R) immunotherapies and pre|CISION(TM) tumour targeted chemotherapies. This approach is designed to address the lack of a durable response to current cancer immunotherapies experienced by most patients and reduce the severe systemic toxicities caused by chemotherapies. There are five programmes in the pipeline as well as several global research collaborations and licensing partnerships. Avacta's lead programme, AVA6000, is a pre|CISION(TM) tumour-targeted form of the established chemotherapy doxorubicin. AVA6000 is in Phase I clinical trials in patients with locally advanced or metastatic selected solid tumours.

The Affimer(R) platform is an alternative to antibodies that has been designed to address many of the drawbacks of antibodies which, despite their shortcomings, currently dominate the immuno-diagnostics and immuno-therapeutics markets.

The pre|CISION(TM) tumour targeting platform can be used to modify a chemotherapy in order to selectively release the active drug in tumour tissue thereby reducing the systemic exposure that causes damage to healthy tissues. pre|CISION(TM) modified chemotherapies are designed to reduce the side effects and improve the overall safety and therapeutic potential of these powerful anti-cancer treatments.

Avacta's Diagnostics Division develops and supplies a broad range of in-vitro diagnostic (IVD) solutions. The Division is growing rapidly through an M&A strategy to deliver a global scale IVD business providing market leading solutions for healthcare professionals and consumers to inform treatment and monitor health and well-being. In October 2022, Avacta acquired Launch Diagnostics which serves the hospital pathology laboratory market in the UK and Europe. In May 2023, Avacta acquired Coris Bioconcept a Belgium based lateral flow test developer and manufacturer adding a broad range of marketed professional-use rapid tests into the Diagnostics Division. Avacta Diagnostic's research and development centre in Wetherby, UK uses its proprietary Affimer(R) platform to differentiate immunodiagnostic products to provide marketing leading performance.

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGEANKPASLDEEA

(END) Dow Jones Newswires

June 28, 2023 06:00 ET (10:00 GMT)

Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Avacta Charts.
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Avacta Charts.